ENANTA PHARMACEUTICALS INC's ticker is ENTA and the CUSIP is 29251M106. A total of 152 filers reported holding ENANTA PHARMACEUTICALS INC in Q1 2016. The put-call ratio across all filers is 1.74 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $342,584 | -27.9% | 30,670 | +38.1% | 0.00% | – |
| Q2 2023 | $475,294 | -39.9% | 22,210 | +13.7% | 0.00% | – |
| Q1 2023 | $790,198 | -24.2% | 19,540 | -12.8% | 0.00% | – |
| Q4 2022 | $1,042,746 | -60.6% | 22,415 | -56.1% | 0.00% | -100.0% |
| Q3 2022 | $2,647,000 | -55.6% | 51,029 | -59.6% | 0.00% | -66.7% |
| Q2 2022 | $5,966,000 | -24.3% | 126,204 | +14.0% | 0.00% | 0.0% |
| Q1 2022 | $7,882,000 | +76.1% | 110,729 | +85.0% | 0.00% | +50.0% |
| Q4 2021 | $4,476,000 | +238.8% | 59,854 | +157.4% | 0.00% | +100.0% |
| Q3 2021 | $1,321,000 | +17.0% | 23,250 | -9.4% | 0.00% | – |
| Q2 2021 | $1,129,000 | -10.8% | 25,650 | 0.0% | 0.00% | -100.0% |
| Q1 2021 | $1,265,000 | +17.6% | 25,650 | +0.3% | 0.00% | 0.0% |
| Q4 2020 | $1,076,000 | -8.1% | 25,570 | 0.0% | 0.00% | 0.0% |
| Q3 2020 | $1,171,000 | -20.0% | 25,570 | -12.3% | 0.00% | 0.0% |
| Q2 2020 | $1,463,000 | -2.4% | 29,140 | 0.0% | 0.00% | 0.0% |
| Q1 2020 | $1,499,000 | -16.7% | 29,140 | 0.0% | 0.00% | 0.0% |
| Q4 2019 | $1,800,000 | -41.6% | 29,140 | -43.2% | 0.00% | -50.0% |
| Q3 2019 | $3,082,000 | -32.7% | 51,300 | -5.5% | 0.00% | -33.3% |
| Q2 2019 | $4,582,000 | +5.2% | 54,300 | +19.1% | 0.00% | 0.0% |
| Q1 2019 | $4,356,000 | +34.9% | 45,600 | 0.0% | 0.00% | +50.0% |
| Q4 2018 | $3,230,000 | -13.8% | 45,600 | +4.0% | 0.00% | 0.0% |
| Q3 2018 | $3,746,000 | -21.8% | 43,830 | +6.0% | 0.00% | -33.3% |
| Q2 2018 | $4,790,000 | +68.1% | 41,330 | +17.3% | 0.00% | +50.0% |
| Q1 2018 | $2,850,000 | -41.0% | 35,230 | -57.2% | 0.00% | -33.3% |
| Q4 2017 | $4,827,000 | +12.0% | 82,260 | -10.7% | 0.00% | 0.0% |
| Q3 2017 | $4,311,000 | +71.6% | 92,120 | +31.9% | 0.00% | +50.0% |
| Q2 2017 | $2,512,000 | +7.4% | 69,820 | -8.0% | 0.00% | 0.0% |
| Q1 2017 | $2,338,000 | -47.2% | 75,910 | -42.5% | 0.00% | -50.0% |
| Q4 2016 | $4,424,000 | +21.7% | 132,060 | -3.3% | 0.00% | +33.3% |
| Q3 2016 | $3,636,000 | +151.5% | 136,630 | +108.4% | 0.00% | +200.0% |
| Q2 2016 | $1,446,000 | +71.3% | 65,560 | +128.0% | 0.00% | 0.0% |
| Q1 2016 | $844,000 | +6.3% | 28,750 | +19.6% | 0.00% | 0.0% |
| Q4 2015 | $794,000 | -6.7% | 24,040 | +2.1% | 0.00% | 0.0% |
| Q3 2015 | $851,000 | -19.9% | 23,540 | -0.3% | 0.00% | 0.0% |
| Q2 2015 | $1,062,000 | +142.5% | 23,600 | +65.0% | 0.00% | – |
| Q1 2015 | $438,000 | -16.4% | 14,300 | +38.8% | 0.00% | – |
| Q4 2014 | $524,000 | +28.4% | 10,300 | 0.0% | 0.00% | – |
| Q3 2014 | $408,000 | +21.4% | 10,300 | +32.1% | 0.00% | – |
| Q2 2014 | $336,000 | +11100.0% | 7,800 | +10163.2% | 0.00% | – |
| Q1 2014 | $3,000 | +50.0% | 76 | 0.0% | 0.00% | – |
| Q4 2013 | $2,000 | -84.6% | 76 | -86.8% | 0.00% | – |
| Q3 2013 | $13,000 | -45.8% | 576 | -57.4% | 0.00% | – |
| Q2 2013 | $24,000 | – | 1,352 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Krensavage Asset Management, LLC | 511,186 | $43,686,000 | 11.23% |
| GREAT POINT PARTNERS LLC | 210,400 | $17,981,000 | 2.80% |
| ARMISTICE CAPITAL, LLC | 456,000 | $38,970,000 | 2.34% |
| Matarin Capital Management, LLC | 210,208 | $17,964,376,000 | 1.16% |
| Sapphire Star Partners LP | 8,168 | $698,000 | 0.70% |
| Granahan Investment Management | 103,320 | $8,830,000 | 0.48% |
| FARALLON CAPITAL MANAGEMENT LLC | 867,500 | $74,137,000 | 0.44% |
| 361 CAPITAL LLC | 19,040 | $1,627,000 | 0.35% |
| ALGERT GLOBAL LLC | 17,922 | $1,532,000 | 0.33% |
| AlphaMark Advisors, LLC | 9,310 | $796,000 | 0.32% |